Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

Doggybone DNA COVID-19 vaccine can effectively neutralize SARS-CoV-2 variants

Doggybone DNA COVID-19 vaccine can effectively neutralize SARS-CoV-2 variants

Combination therapy shows promise for treating triple-negative breast cancer

Combination therapy shows promise for treating triple-negative breast cancer

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Neutrophils found to initiate COVID-19-associated olfactory epithelial damage in hamsters

Neutrophils found to initiate COVID-19-associated olfactory epithelial damage in hamsters

COVID-19 symptoms found to vary in different immune contexts

COVID-19 symptoms found to vary in different immune contexts

New drug combination may prevent GvHD after stem cell transplantation for blood cancers

New drug combination may prevent GvHD after stem cell transplantation for blood cancers

Combination treatment can provide long remissions for young patients with chronic lymphocytic leukemia

Combination treatment can provide long remissions for young patients with chronic lymphocytic leukemia

Donor cells with clonal hematopoiesis may improve bone marrow transplant outcomes

Donor cells with clonal hematopoiesis may improve bone marrow transplant outcomes

Results of high-impact clinical trials could affect kidney-related medical care

Results of high-impact clinical trials could affect kidney-related medical care

Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma

Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Study looks at immunosuppressants and COVID vaccine efficacy

Study looks at immunosuppressants and COVID vaccine efficacy

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

'Cold' tumors can be turned 'hot' with extremely low doses of radiation, study shows

'Cold' tumors can be turned 'hot' with extremely low doses of radiation, study shows

Three new guidelines released for treatment and management of systemic vasculitis

Three new guidelines released for treatment and management of systemic vasculitis

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Combination therapy places no greater burden on early-stage breast cancer patients

Combination therapy places no greater burden on early-stage breast cancer patients

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL